NeoGenomics Schedules its Second Quarter 2022 Earnings Release for August 9, 2022Accesswire • 07/15/22
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of InvestorsBusiness Wire • 06/27/22
NeoGenomics (NEO) Surges 6.4%: Is This an Indication of Further Gains?Zacks Investment Research • 06/27/22
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of InvestorsBusiness Wire • 06/24/22
The Law Offices of Frank R. Cruz Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of InvestorsBusiness Wire • 06/24/22
Inivata and Collaborators Announce New Data Demonstrating Clinical Potential of its RaDaR™ MRD Test in HR+ HER2- Breast CancerGlobeNewsWire • 06/21/22
NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast CancerAccesswire • 06/21/22
NeoGenomics To Participate In Multiple Upcoming Institutional Investor ConferencesAccesswire • 06/03/22
NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services LaboratoryAccesswire • 06/03/22
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR(R) MRD and InVisionFirst(R)-Lung Tests at the 2022 ASCO Annual MeetingAccesswire • 05/10/22
Inivata and Collaborators to Present New Data Further Validating the Application of its RaDaR® MRD and InVisionFirst®-Lung Tests at the 2022 ASCO Annual MeetingGlobeNewsWire • 05/10/22
NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy SubsidiaryAccesswire • 05/09/22
NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE(R) DNA and RNA AssayAccesswire • 04/25/22
Earnings Preview: NeoGenomics (NEO) Q1 Earnings Expected to DeclineZacks Investment Research • 04/20/22
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages NeoGenomics, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - NEOPRNewsWire • 04/18/22
NEO Investor Notice : ROSEN, Top Ranked Investor Counsel, Encourages NeoGenomics, Inc. Investors with Losses Exceeding $100K to Inquire About Securities Class Action Investigation - NEONewsfile Corp • 04/17/22
NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay MRD Assay at AACR 2022Accesswire • 04/11/22